Bevacizumab, Atezolizumab, and Acetylsalicylic Acid in Recurrent, Platinum-Resistant Ovarian Cancer: The EORTC 1508-GCG Phase II StudySusana Banerjee, George Coukos, Fernanda Herrera et al.|Clinical Cancer Research|2025Cited by 12
Maintenance olaparib in patients (pts) with platinum-sensitive relapsed ovarian cancer (PSROC) by somatic (s) or germline (g) BRCA and other homologous recombination repair (HRR) gene mutation status: Overall survival (OS) results from the ORZORA study.Sandro Pignata, Andrew R. Clamp, Amit M. Oza et al.|Journal of Clinical Oncology|2022Cited by 5
Early stage ovarian cancer clinical behavior according to FIGO 2014 Staging changes with a focus on IC subtype: data from prospective GEICO registry.Ignacio Romero, Cristina Churruca, Andrés Redondo et al.|Journal of Clinical Oncology|2015Cited by 1
Supplementary Table S1 from Bevacizumab, Atezolizumab, and Acetylsalicylic Acid in Recurrent, Platinum-Resistant Ovarian Cancer: The EORTC 1508-GCG Phase II StudySusana Banerjee, George Coukos, Eleonora Ghisoni et al.|Unknown|2025Cited by 0
Supplementary Figure S3 from Bevacizumab, Atezolizumab, and Acetylsalicylic Acid in Recurrent, Platinum-Resistant Ovarian Cancer: The EORTC 1508-GCG Phase II StudySusana Banerjee, George Coukos, Eleonora Ghisoni et al.|Unknown|2025Cited by 0